Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations

Michael Hardy, Jonathan Douxfils, Marion Bareille, Sarah Lessire, Isabelle Gouin-Thibault, Pierre Fontana, Thomas Lecompte, François Mullier

Research output: Contribution to journalLetterpeer-review

1 Downloads (Pure)

Abstract

We read with much interest the recent observational study of Nougier et al., which aimed at studying thrombin generation (TG) and fibrinolysis profiles of COVID-19 patients admitted to an intensive care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic heparin.[1] They reported that thrombin potential remained within normal range despite heparin and that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL tPA (referred to as 'TEM-tPA'), they reported decreased clot lysis in COVID-19 patients, which was more pronounced in patients who presented a thrombotic event, compared to event-free patients.

Original languageEnglish
JournalJournal of thrombosis and haemostasis : JTH
Early online date2020
DOIs
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations'. Together they form a unique fingerprint.

Cite this